China Healthcare Weekly – 13th January 2026
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$…
Address: Rongjing Dong Street, Beijing Economic and Technological Development Zone Zip: 100176
Tel: -111549.584415584
Web: http://www.biotechplc.com/
BioteQ Bio-Pharmaceutical Co., Ltd. was established in August 2000, China and Cuba in the field of biotechnology, the highest level, the largest investment cooperation projects, to research and development and production of the treatment of malignant tumors, the source resistance, monoclonal antibodies and vaccines undertake the major projects of the National High-Tech Research and Development Plan, the national high-tech industrialization demonstration project for the main direction.
100 Thai Biological Pharmaceutical has China’s first world-class antibodies humanized technology platform, represents a core technology of the international bio-pharmaceutical development and direction of the mainstream. The company designed and built the production line of China’s first fully automated large-scale mammalian cell culture, which is currently the largest, most comprehensive facilities, the most technologically advanced large-scale cell culture technology platform.
The Biological Pharmaceutical Baitai successfully developed China’s first personal humanized monoclonal antibody drug – Taixinsheng nimotuzumab the drug in April 2005 Biology I class drug certificate issued by the State Food and Drug Administration , fill our humanized monoclonal antibody drugs blank. The Taixinsheng ® can specifically target the tumor cells to targeted therapies in killing tumor cells without damaging normal tissue, and represent the latest developments in the direction of the field of cancer treatment. Clinical studies have shown that Taixinsheng ® single-agent or combined radiotherapy and chemotherapy for head and neck cancer, colorectal cancer, glioma, non-small cell lung cancer efficacy, significant side effects is low, with high clinical value.
Same time the Biological Pharmaceutical Baitai actively carry out international technical transformation, is committed to nurturing the capability of independent innovation, new drugs are being developed, including the EGF vaccine for the treatment of cancer, psoriasis and rheumatoid arthritis, a humanized anti-CD6 single anti for reversal of organ transplant rejection anti-CD3 mAb.
The Biological Pharmaceutical development Baitai target large modern biopharmaceutical company, to improve antibody drug research and development capabilities and production levels, to improve the health of the people for the purpose, internationalization, industrialization, standardization, the scale of the operation mode, is committed to the latest achievements of the development of biotechnology into the cause of the health of the 21st century, and continuous dedication to the community is the most advanced, most excellent antibody drugs, witnessed the rise of China’s life sciences and biomedicine with you!
Research and Development
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech,…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Elpiscience filing for a Hong Kong IPO after US$250M in financing, Zhejiang Medicine planning an HKEX spin-off for ADC…
Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s…
China is rapidly maturing into a global hub for innovation, offering speed, scale, and cost advantages in clinical trials that few markets can match. Andy Liu, Managing Director China for…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive…
See our Cookie Privacy Policy Here